Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients

Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients

Wen Shi,1 Juan Wu,1 Qi Tan,1 Chun-Mei Hu,2 Xia Zhang,2 Hong-Qiu Pan,3 Zhen Yang,4 Meng-Yu He,1 Min Yu,1 Bo Zhang,5 Wei-Ping Xie,1 Hong Wang11Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital. The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu...

Full description

Bibliographic Details
Main Authors:	Shi W, Wu J, Tan Q, Hu CM, Zhang X, Pan HQ, Yang Z, He MY, Yu M, Zhang B, Xie WP, Wang H
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-05-01
Series:	Infection and Drug Resistance
Subjects:	IDO MDR-TB LC-MS/MS cavitary lung lesion
Online Access:	https://www.dovepress.com/plasma-indoleamine-23-dioxygenase-activity-as-a-potential-biomarker-fo-peer-reviewed-article-IDR

Similar Items

Indoleamine 2, 3-Dioxygenase-Mediated Tryptophan Catabolism: A Leading Star or Supporting Act in the Tuberculosis and HIV Pas-de-Deux?
by: Clement Gascua Adu-Gyamfi, et al.
Published: (2019-10-01)

Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
by: Lieve Brochez, et al.
Published: (2021-12-01)

Factors associated with multidrug-resistant tuberculosis
by: Md Nurul Amin, et al.
Published: (2009-01-01)

Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
by: Fanta Desissa, et al.
Published: (2018-04-01)

Trends in multidrug-resistant tuberculosis
by: I. M. F. Dias-Baptista, et al.
Published: (2008-01-01)

Drug susceptibilities of Mycobacterium tuberculosis against injectable second-line drugs from Pakistan: Analysis of multidrug-resistant and non-multidrug-resistant tuberculosis strains
by: Kauser Jabeen, et al.
Published: (2015-01-01)

Evaluation of mode of indoleamine 2,3-dioxygenase 1 inhibition by 4,7-dichloroquinolines
by: Niku Moni Das, et al.
Published: (2023-12-01)

Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer
by: Anshuman Panda, et al.
Published: (2021-07-01)

Risk Factors for Multidrug-resistant Tuberculosis
by: Cleopas Martin Rumende
Published: (2018-04-01)

Indoleamine-2,3-Dioxygenase 1 Deficiency Suppresses Seizures in Epilepsy
by: Ning Deng, et al.
Published: (2021-02-01)

Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity
by: Mincheol Kwon, et al.
Published: (2019-01-01)

Untargeted metabolomics of pulmonary tuberculosis patient serum reveals potential prognostic markers of both latent infection and outcome
by: Xuezhi Wang, et al.
Published: (2022-11-01)

Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011
by: Hoa Binh Nguyen, et al.
Published: (2016-06-01)

Outbreak of Tuberculosis and Multidrug-Resistant Tuberculosis, Mbuji-Mayi Central Prison, Democratic Republic of the Congo
by: Michel Kaswa Kayomo, et al.
Published: (2018-11-01)

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
by: Monadil H. Ali, et al.
Published: (2019-07-01)

Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway
by: Xueyuan Yang, et al.
Published: (2021-06-01)

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany
by: Barbara Eker, et al.
Published: (2008-11-01)

Beneficial or detrimental activity of regulatory T cells, indoleamine 2,3-dioxygenase, and heme oxygenase-1 in the lungs is influenced by the level of virulence of Mycobacterium tuberculosis strain infection
by: Vasti Lozano-Ordaz, et al.
Published: (2023-05-01)

<i>Indoleamine 2,3-Dioxygenase 2</i> Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation
by: Kento Fujii, et al.
Published: (2020-08-01)

Prevalence of Multidrug-Resistant Tuberculosis in Dalian, China: A Retrospective Study
by: Du L, et al.
Published: (2021-03-01)

Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy
by: Xiaofei Miao, et al.
Published: (2021-03-01)

Indoleamine 2,3-Dioxygenase Activity During Acute Toxoplasmosis and the Suppressed T Cell Proliferation in Mice
by: Christoph-Martin Ufermann, et al.
Published: (2019-06-01)

Host-directed therapies for multidrug resistant tuberculosis
by: Alimuddin Zumla, et al.
Published: (2016-01-01)

Identification of Serum Cytokine Biomarkers Associated with Multidrug Resistant Tuberculosis (MDR-TB)
by: Gloria Ivy Mensah, et al.
Published: (2021-10-01)

Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia
by: Assefa D, et al.
Published: (2017-07-01)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
by: Mohammad Javad Nasiri, et al.
Published: (2022-11-01)

Multidrug resistant tuberculosis versus non-tuberculous mycobacterial infections: a CT-scan challenge
by: Shahram Kahkouee, et al.
Published: (2013-04-01)

Multidrug resistant tuberculosis versus non-tuberculous mycobacterial infections: a CT-scan challenge
by: Shahram Kahkouee, et al.

Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France
by: Isabelle Bonnet, et al.
Published: (2022-06-01)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
by: Jay Achar, et al.
Published: (2017-10-01)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by: Pengbo Yang, et al.
Published: (2023-07-01)

Trends in multidrug-resistant tuberculosis in Tehran, Iran: an analysis of published data
by: Nasiri, Mohammad Javad, et al.
Published: (2019-08-01)

Hubungan Peran Keluarga dan Kepatuhan Pasien TB MDR di RSUD Dr. Soetomo Surabaya [The Role of Family in Improving Multidrug-Resistant Tuberculosis Patient Compliance]
by: Safira Nur Ainiyah, et al.
Published: (2019-01-01)

Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study
by: Ji Lecai, et al.
Published: (2023-06-01)

Prevalence of Multi-Drug Resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa – A High Tuberculosis Endemic Area of Pakistan
by: SAJID ALI, et al.
Published: (2020-01-01)

The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance
by: Knut A. Hestad, et al.
Published: (2017-10-01)

Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy
by: Roberta Liberato Pagni, et al.
Published: (2022-11-01)

Genetic Deficiency of Indoleamine 2,3-dioxygenase Aggravates Vascular but Not Liver Disease in a Nonalcoholic Steatohepatitis and Atherosclerosis Comorbidity Model
by: Aastha Arora, et al.
Published: (2022-05-01)

Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation
by: Chao Yang, et al.
Published: (2021-09-01)

Multidrug-Resistant Tuberculosis In A Referral Center In Rome: 2011– 2016
by: Cannas A, et al.
Published: (2019-10-01)